An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine)

Biochem J. 1995 Nov 1;311 ( Pt 3)(Pt 3):867-72. doi: 10.1042/bj3110867.

Abstract

Tice substrain BCG is used clinically as an immunotherapeutic agent against superficial bladder cancer. A boiling-water extract of this BCG showed anti-tumour activity against a murine S180 sarcoma model and was fractionated into three fractions, A, B and C, by the use of Sephadex LH-20 chromatography. An anti-tumour glucan, PS1A1, was isolated from fraction PS1A with Sephadex G-75. The molecular mass of PS1A1 was between 65 and 87 kDa by Sephadex G-100 chromatography. The structure of PS1A1 was investigated by one- and two-dimensional NMR spectroscopy and methylation analysis and was demonstrated to be primarily 1-->6-alpha-linked glucose units. We postulate that the repeating unit is: [Formula: see text]

MeSH terms

  • Animals
  • Antineoplastic Agents / analysis*
  • Antineoplastic Agents / isolation & purification
  • Antineoplastic Agents / pharmacology*
  • BCG Vaccine / chemistry*
  • Carbohydrate Sequence
  • Chromatography, Gas
  • Drug Screening Assays, Antitumor
  • Female
  • Glucans / analysis*
  • Glucans / isolation & purification
  • Glucans / pharmacology*
  • Mice
  • Molecular Sequence Data
  • Polysaccharides / analysis*
  • Polysaccharides / isolation & purification
  • Polysaccharides / pharmacology*
  • Sarcoma 180 / drug therapy

Substances

  • Antineoplastic Agents
  • BCG Vaccine
  • Glucans
  • PS1A1 glucan
  • Polysaccharides